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CRISPR/Cas9 has recently been introduced as a gene editing tool and shows considerable promise. In this
issue of Cell Stem Cell,Mandal et al. (2014) show efficient CRISPR/Cas9-mediated ablation of the CCR5 and
B2M genes in primary human hematopoietic cells, two editing strategies that are potentially translatable into
clinical application.Experimental medicine through the use of
cell and stem cell therapies has the poten-
tial to transform the way we treat specific
diseases. In particular, the manipulation
of the human hematopoietic system has
clinically led the gene and cell therapy
field. Gene-modified autologous stem
and mature T cell products have now
shown considerable clinical efficacy in
the treatment of a number of monogenic
diseases and acquired conditions. To
date, gene delivery has relied on the use
of integrating vectors that cannot be
directed to a specific gene or locus and
thus have the potential for semirandom
genomic disruption.
The last 5 years have seen the emer-
gence of gene editing strategies, including
zinc-finger nucleases (ZFNs) and tran-
scription-activator-like effector nucleases
(TALENs) (e.g., Genovese et al., 2014).
The principles of gene editing are those
of DNA repair: we achieve site-specific
DNA modification by damaging the
genome and then taking advantage of
the cell’s DNA repair mechanisms. In gen-
eral terms, the DNA repair machinery can
opt for either nonhomologous end join-
ing (NHEJ) or homology-directed repair
(HDR) if a DNA template is made available.
Simultaneous generation of two or more
double-strand breaks (DSBs) can also
lead to genomic rearrangements such as
deletions, inversions, and translocations.
The latest contender in the gene editing
field is the CRISPR/Cas9 system, which
consists of a nuclease protein (Cas9)
that induces DSBs in target DNA after be-
ing directed by a short guide RNA
molecule (gRNA). The advantages of
CRISPR/Cas9 include the versatility of
targeting and the ease of design, whichallows for high-throughput gene editing
(Zhou et al., 2014b). The design of the
gRNA requires special attention, as this
appears to determine the efficiency as
well as the specificity of the approach.
In this issue of Cell Stem Cell, Mandal
et al. report the ablation of the CCR5
and B2M genes using CRISPR/Cas9 in
human CD4+ T cells and hematopoietic
CD34+ stem cells, respectively. Whereas
CRISPR/Cas9 gene targeting has been
previously successfully demonstrated in
cell lines, the significant advance in this
report lies in the proof of principle for suc-
cessful gene ablation in primary human
hematopoietic cells.
The B2M gene encodes for beta-2
microglobulin, a protein associated with
the major histocompatibility complex
(MHC) class I, or human leukocyte antigen
(HLA) class I in humans. With the disrup-
tion of B2M, MHC class I molecules are
not expressed on the cell surface and
CD8+ T cell immunogenicity and alloreac-
tivity can be avoided (Riolobos et al.,
2013), which could potentially generate a
‘‘universal’’ cell for allotransplantation. If
successful, this approach could result
in generic, cost-effective, off-the-shelf
T cells that can be engineered for antiviral
and anticancer immunotherapy (Torikai
et al., 2013).
In the current report, the efficacy of
multiple gRNAs targeting B2M was
initially studied in HEK293T cells where a
disruption efficiency of 6.9%–48% was
achieved. However, a drop in the rate of
NHEJ was found when these same
gRNAs were moved to human primary
CD4+ T cells (1.4%–4.7%). The authors
hypothesized that introducing two
different gRNAs targeting a specific locusCell Stem Cell 15,could result in a frequency of defined de-
letions, as described previously in other
contexts. The results support the validity
of the dual gRNA strategy: the predicted
deletion was generally observed at rates
similar to the NHEJ seen in the gRNAs
when they were transfected separately.
One of the pairs (crB2M_13+8) resulted
in 18% of surface B2M ablation, implying
that a synergic interaction between the
two guides took place. This augmented
effect in the dual gRNA CRISPR/Cas9
context has also been described inmouse
embryos (Zhou et al., 2014a).
The CCR5 gene encodes for chemo-
kine receptor 5, the main coreceptor for
the human immunodeficiency virus (HIV)
in human T cells. It also became a major
target for HIV treatment after the Berlin
patient was reported as ‘‘cured’’ from
the virus after allogeneic hematopoietic
transplant from a CCR5 deficient donor
(Hu¨tter et al., 2009). Research has tried
to replicate this with gene therapy strate-
gies to disrupt the CCR5 gene with ZFNs
(Holt et al., 2010) and such efforts were
recently reported with the CRISPR/Cas9
system in hiPSCs (Ye et al., 2014).
Mandal et al. also looked to disrupt
CCR5 expression in human CD34+ he-
matopoietic stem cells. Similar to the
CD4+ T cell approach, several guides
were first analyzed in the K562 cell line
and then applied to CD34+ cells. This
time, however, NHEJ rates in primary
CD34+ cells (about 14%) were more
similar to those observed in the K562s
and comparable to the 17% NHEJ rate
described in the same cells with ZFNs
(Holt et al., 2010). Interestingly, when the
dual gRNA approach was applied to pri-
mary CD34+ cells, authors observed anNovember 6, 2014 ª2014 Elsevier Inc. 529
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Previewsincreased deletion efficiency of 20%–
42%, values that could have a bigger
impact when applied into functional and
preclinical models. It is important to note
that the modified CD34+ cells showed
normal maintenance of stemness and
normal differentiation function when
tested in in vitro differentiation and in vivo
murine reconstitution assays.
Ideally, gene editing should result in
controlled, site-specific modifications.
However, off-target effects have been
described in all gene editing systems
and we might expect even more off-tar-
geting events if two (instead of one)
gRNAs are introduced into cells. In the
work of Mandal et al., the on-target abla-
tion pattern and off-targeting safety was
analyzed by next generation sequencing
(NGS). While NHEJ is the main event
in single gRNA transfections (5.1%–
13.3%), they found that deletion takes
the lead in the dual gRNA context
(20.0% to 42.1%), with NHEJ and inver-
sions set aside as minor events (2.5%–
3.1%). Nevertheless, these disruptions
still led to the silencing of CCR5. In terms
of off-target disruption, such events
were exceedingly rare. They used cap-
ture sequence reads at predicted off-
target sites in the genome and found
that only one site in the homologous
CCR2 gene was statistically significantly
mutated above control levels. Structural
variations such as inversions or translo-530 Cell Stem Cell 15, November 6, 2014 ª2cations were also not evident at off-
target sites.
Comparing the decreased efficiency
of editing in T cells to that of editing in
CD34+ cells, it is tempting to speculate
that some cell types are naturally more
refractory to CRISPR/Cas9 gene editing
than others. However, as pointed out
by the authors, the differences seen
could be due to multiple experimental
factors: a real resistance of the T cell
DNA repair machinery to edition, gene
delivery issues, T cell defense against
foreign DNA, or just the differences be-
tween gRNA sequences.
In summary, the work of Mandal et al.
(2014) is one of the first steps toward
successful gene editing of primary hu-
man T and CD34+ cells with the
CRISPR/Cas9 system. The potential
applicability of targeted gene disruption
is significant and the authors highlight
its possible use in highly prevalent condi-
tions such as b-thalasseamia and sickle
cell anemia where disruption/deletion of
BCL11A could increase fetal hemoglobin
expression. The use of highly specific
gene editing is also the first step to cor-
recting genes by homology directed
repair, which, if efficient, would over-
come any concerns surrounding current
gene augmentation strategies. Given
the current momentum of CRISPR/Cas9
research and the rapid advances in
gene modification and gene delivery014 Elsevier Inc.technologies, the move to human clinical
application is unlikely to be too far away.REFERENCES
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